Overview of the lifting of restrictions on A-shares | December 30

According to Zhichun Financial APP, on December 30, a total of 37 listed companies had their restricted shares unlocked, with a total market value of approximately 12.254 billion yuan. Today's specific situation of the restricted shares unlocked is as follows: Stock Abbreviation Stock Code Restricted Stock Type Number of Stocks Unlocked Henan Yuneng Holdings 001896 Placement of A-shares for original shareholders 0.205 billion Datang Telecom Technology 600198 Placement of A-shares for original shareholders 0.428 billion China National Software & Service 600536 Stock-based Incentive restricted circulation 0.7513 million Xiamen Tungsten 600549 Stock-based Incentive restricted circulation 3.6369 million Yueyang Forest & Paper 600963 Stock-based Incentive restricted circulation 0.27 million

Zhitong FinanceDec 30, 2024 09:00

Tianjin Development Subsidiary to Repurchase Shares, Grant Shares Under Share Award Scheme

MT NewswiresDec 23, 2024 16:19

TIANJIN DEV (00882.HK) subsidiary Tianjin Lisheng Pharmaceutical suggests a buyback with a funding limit of 0.153 billion yuan.

TIANJIN DEV (00882.HK) announced that its subsidiary Tianjin Lisheng Pharmaceutical (002393.SZ) proposes to repurchase shares through centralized bidding trading starting immediately for a total amount of no less than 76.5 million yuan and not exceeding 0.153 billion yuan within twelve months.

AASTOCKSDec 22, 2024 21:38

Tianjin Lisheng Pharmaceutical (002393.SZ): Plans to launch the 2024 restricted stock incentive plan.

On December 20, Gelonghui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) announced its 2024 Stock-based Incentive Plan, which proposes to grant no more than 7,210,000 shares of restricted stocks to the incentive objects, accounting for approximately 2.80% of the company’s total share capital of 257,942,988 shares. Among these, 5,770,000 shares of restricted stocks will be granted initially, accounting for 80.03% of the total number of restricted stocks; about 1,440,000 shares of restricted stocks will be reserved, accounting for 19.97% of the total number of restricted stocks. After the implementation of this incentive plan, the company's entire effective equity incentive plan will be.

Gelonghui FinanceDec 20, 2024 22:19

Tianjin DEV (00882.HK) subsidiary Tianjin Lisheng Pharmaceutical plans to repurchase shares and adopt a stock incentive plan.

On December 20, Grizzly Holdings announced that TIANJIN DEV (00882.HK) has approved a share buyback plan at the Board of Directors of Tianjin Lisheng Pharmaceutical (a non-wholly-owned subsidiary indirectly listed on the Shenzhen Stock Exchange) on December 20, 2024. Accordingly, starting from December 21, 2024, within a period of twelve months, Tianjin Lisheng Pharmaceutical is allowed to repurchase its ordinary shares through centralized bidding on the Shenzhen Stock Exchange at the current market price, with a total amount not less than 76.5 million yuan and not exceeding 0.153 billion yuan. The Board of Directors of Tianjin Lisheng Pharmaceutical recommends that this be approved by its Shareholders at the Shareholders' meeting.

Gelonghui FinanceDec 20, 2024 21:57

Express News | Tianjin Lisheng Pharmaceutical: plans to repurchase shares for 76.5 million yuan to -0.153 billion yuan.

BreakingsDec 20, 2024 21:48